Report Detail
Global Bladder Cancer Targeted Drug Market 2025 by Company, Regions, Type and Application, Forecast to 2031
- RnM4652833 |
- 05 December, 2025 |
- Global |
- 84 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Bladder Cancer Targeted Drug market size was valued at US$ 929 million in 2024 and is forecast to a readjusted size of USD 1686 million by 2031 with a CAGR of 9.0% during review period.
Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and tries to limit damage to healthy cells.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Bladder Cancer Targeted Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Bladder Cancer Targeted Drug market size and forecasts, in consumption value ($ Million), 2020-2031
Global Bladder Cancer Targeted Drug market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Bladder Cancer Targeted Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Bladder Cancer Targeted Drug market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Bladder Cancer Targeted Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Bladder Cancer Targeted Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Merck KGaA, Roche, Astellas, Janssen Biotech, Bristol-Myers Squibb, Merck & Co., Gilead Sciences, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Bladder Cancer Targeted Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Erdafitinib (Balversa)
Other
Market segment by Application
Hospital
Retail Pharmacy
Other
Market segment by players, this report covers
Pfizer
Merck KGaA
Roche
Astellas
Janssen Biotech
Bristol-Myers Squibb
Merck & Co.
Gilead Sciences
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Bladder Cancer Targeted Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Bladder Cancer Targeted Drug, with revenue, gross margin, and global market share of Bladder Cancer Targeted Drug from 2020 to 2025.
Chapter 3, the Bladder Cancer Targeted Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Bladder Cancer Targeted Drug market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Bladder Cancer Targeted Drug.
Chapter 13, to describe Bladder Cancer Targeted Drug research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Bladder Cancer Targeted Drug by Type
- 1.3.1 Overview: Global Bladder Cancer Targeted Drug Market Size by Type: 2020 Versus 2024 Versus 2031
- 1.3.2 Global Bladder Cancer Targeted Drug Consumption Value Market Share by Type in 2024
- 1.3.3 Atezolizumab (Tecentriq)
- 1.3.4 Avelumab (Bavencio)
- 1.3.5 Erdafitinib (Balversa)
- 1.3.6 Other
- 1.4 Global Bladder Cancer Targeted Drug Market by Application
- 1.4.1 Overview: Global Bladder Cancer Targeted Drug Market Size by Application: 2020 Versus 2024 Versus 2031
- 1.4.2 Hospital
- 1.4.3 Retail Pharmacy
- 1.4.4 Other
- 1.5 Global Bladder Cancer Targeted Drug Market Size & Forecast
- 1.6 Global Bladder Cancer Targeted Drug Market Size and Forecast by Region
- 1.6.1 Global Bladder Cancer Targeted Drug Market Size by Region: 2020 VS 2024 VS 2031
- 1.6.2 Global Bladder Cancer Targeted Drug Market Size by Region, (2020-2031)
- 1.6.3 North America Bladder Cancer Targeted Drug Market Size and Prospect (2020-2031)
- 1.6.4 Europe Bladder Cancer Targeted Drug Market Size and Prospect (2020-2031)
- 1.6.5 Asia-Pacific Bladder Cancer Targeted Drug Market Size and Prospect (2020-2031)
- 1.6.6 South America Bladder Cancer Targeted Drug Market Size and Prospect (2020-2031)
- 1.6.7 Middle East & Africa Bladder Cancer Targeted Drug Market Size and Prospect (2020-2031)
2 Company Profiles
- 2.1 Pfizer
- 2.1.1 Pfizer Details
- 2.1.2 Pfizer Major Business
- 2.1.3 Pfizer Bladder Cancer Targeted Drug Product and Solutions
- 2.1.4 Pfizer Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
- 2.1.5 Pfizer Recent Developments and Future Plans
- 2.2 Merck KGaA
- 2.2.1 Merck KGaA Details
- 2.2.2 Merck KGaA Major Business
- 2.2.3 Merck KGaA Bladder Cancer Targeted Drug Product and Solutions
- 2.2.4 Merck KGaA Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
- 2.2.5 Merck KGaA Recent Developments and Future Plans
- 2.3 Roche
- 2.3.1 Roche Details
- 2.3.2 Roche Major Business
- 2.3.3 Roche Bladder Cancer Targeted Drug Product and Solutions
- 2.3.4 Roche Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
- 2.3.5 Roche Recent Developments and Future Plans
- 2.4 Astellas
- 2.4.1 Astellas Details
- 2.4.2 Astellas Major Business
- 2.4.3 Astellas Bladder Cancer Targeted Drug Product and Solutions
- 2.4.4 Astellas Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
- 2.4.5 Astellas Recent Developments and Future Plans
- 2.5 Janssen Biotech
- 2.5.1 Janssen Biotech Details
- 2.5.2 Janssen Biotech Major Business
- 2.5.3 Janssen Biotech Bladder Cancer Targeted Drug Product and Solutions
- 2.5.4 Janssen Biotech Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
- 2.5.5 Janssen Biotech Recent Developments and Future Plans
- 2.6 Bristol-Myers Squibb
- 2.6.1 Bristol-Myers Squibb Details
- 2.6.2 Bristol-Myers Squibb Major Business
- 2.6.3 Bristol-Myers Squibb Bladder Cancer Targeted Drug Product and Solutions
- 2.6.4 Bristol-Myers Squibb Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
- 2.6.5 Bristol-Myers Squibb Recent Developments and Future Plans
- 2.7 Merck & Co.
- 2.7.1 Merck & Co. Details
- 2.7.2 Merck & Co. Major Business
- 2.7.3 Merck & Co. Bladder Cancer Targeted Drug Product and Solutions
- 2.7.4 Merck & Co. Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
- 2.7.5 Merck & Co. Recent Developments and Future Plans
- 2.8 Gilead Sciences
- 2.8.1 Gilead Sciences Details
- 2.8.2 Gilead Sciences Major Business
- 2.8.3 Gilead Sciences Bladder Cancer Targeted Drug Product and Solutions
- 2.8.4 Gilead Sciences Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
- 2.8.5 Gilead Sciences Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Bladder Cancer Targeted Drug Revenue and Share by Players (2020-2025)
- 3.2 Market Share Analysis (2024)
- 3.2.1 Market Share of Bladder Cancer Targeted Drug by Company Revenue
- 3.2.2 Top 3 Bladder Cancer Targeted Drug Players Market Share in 2024
- 3.2.3 Top 6 Bladder Cancer Targeted Drug Players Market Share in 2024
- 3.3 Bladder Cancer Targeted Drug Market: Overall Company Footprint Analysis
- 3.3.1 Bladder Cancer Targeted Drug Market: Region Footprint
- 3.3.2 Bladder Cancer Targeted Drug Market: Company Product Type Footprint
- 3.3.3 Bladder Cancer Targeted Drug Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Bladder Cancer Targeted Drug Consumption Value and Market Share by Type (2020-2025)
- 4.2 Global Bladder Cancer Targeted Drug Market Forecast by Type (2026-2031)
5 Market Size Segment by Application
- 5.1 Global Bladder Cancer Targeted Drug Consumption Value Market Share by Application (2020-2025)
- 5.2 Global Bladder Cancer Targeted Drug Market Forecast by Application (2026-2031)
6 North America
- 6.1 North America Bladder Cancer Targeted Drug Consumption Value by Type (2020-2031)
- 6.2 North America Bladder Cancer Targeted Drug Market Size by Application (2020-2031)
- 6.3 North America Bladder Cancer Targeted Drug Market Size by Country
- 6.3.1 North America Bladder Cancer Targeted Drug Consumption Value by Country (2020-2031)
- 6.3.2 United States Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 6.3.3 Canada Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 6.3.4 Mexico Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
7 Europe
- 7.1 Europe Bladder Cancer Targeted Drug Consumption Value by Type (2020-2031)
- 7.2 Europe Bladder Cancer Targeted Drug Consumption Value by Application (2020-2031)
- 7.3 Europe Bladder Cancer Targeted Drug Market Size by Country
- 7.3.1 Europe Bladder Cancer Targeted Drug Consumption Value by Country (2020-2031)
- 7.3.2 Germany Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 7.3.3 France Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 7.3.4 United Kingdom Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 7.3.5 Russia Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 7.3.6 Italy Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
8 Asia-Pacific
- 8.1 Asia-Pacific Bladder Cancer Targeted Drug Consumption Value by Type (2020-2031)
- 8.2 Asia-Pacific Bladder Cancer Targeted Drug Consumption Value by Application (2020-2031)
- 8.3 Asia-Pacific Bladder Cancer Targeted Drug Market Size by Region
- 8.3.1 Asia-Pacific Bladder Cancer Targeted Drug Consumption Value by Region (2020-2031)
- 8.3.2 China Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 8.3.3 Japan Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 8.3.4 South Korea Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 8.3.5 India Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 8.3.6 Southeast Asia Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 8.3.7 Australia Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
9 South America
- 9.1 South America Bladder Cancer Targeted Drug Consumption Value by Type (2020-2031)
- 9.2 South America Bladder Cancer Targeted Drug Consumption Value by Application (2020-2031)
- 9.3 South America Bladder Cancer Targeted Drug Market Size by Country
- 9.3.1 South America Bladder Cancer Targeted Drug Consumption Value by Country (2020-2031)
- 9.3.2 Brazil Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 9.3.3 Argentina Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
10 Middle East & Africa
- 10.1 Middle East & Africa Bladder Cancer Targeted Drug Consumption Value by Type (2020-2031)
- 10.2 Middle East & Africa Bladder Cancer Targeted Drug Consumption Value by Application (2020-2031)
- 10.3 Middle East & Africa Bladder Cancer Targeted Drug Market Size by Country
- 10.3.1 Middle East & Africa Bladder Cancer Targeted Drug Consumption Value by Country (2020-2031)
- 10.3.2 Turkey Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 10.3.3 Saudi Arabia Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
- 10.3.4 UAE Bladder Cancer Targeted Drug Market Size and Forecast (2020-2031)
11 Market Dynamics
- 11.1 Bladder Cancer Targeted Drug Market Drivers
- 11.2 Bladder Cancer Targeted Drug Market Restraints
- 11.3 Bladder Cancer Targeted Drug Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Bladder Cancer Targeted Drug Industry Chain
- 12.2 Bladder Cancer Targeted Drug Upstream Analysis
- 12.3 Bladder Cancer Targeted Drug Midstream Analysis
- 12.4 Bladder Cancer Targeted Drug Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Bladder Cancer Targeted Drug. Industry analysis & Market Report on Bladder Cancer Targeted Drug is a syndicated market report, published as Global Bladder Cancer Targeted Drug Market 2025 by Company, Regions, Type and Application, Forecast to 2031. It is complete Research Study and Industry Analysis of Bladder Cancer Targeted Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
